As of 2026-04-20, the EV/EBITDA ratio of Ose Immunotherapeutics SA (OSE.PA) is 1.77. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OSE.PA's latest enterprise value is 88.02 mil EUR. OSE.PA's TTM EBITDA according to its financial statements is 49.82 mil EUR. Dividing these 2 quantities gives us the above OSE.PA EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 7.7x - 11.6x | 9.6x |
| Forward P/E multiples | 7.8x - 15.5x | 11.6x |
| Fair Price | 8.42 - 25.14 | 16.84 |
| Upside | 153.0% - 655.4% | 406.1% |
| Date | EV/EBITDA |
| 2026-04-17 | 1.77 |
| 2026-04-16 | 1.74 |
| 2026-04-15 | 1.70 |
| 2026-04-14 | 1.73 |
| 2026-04-13 | 1.68 |
| 2026-04-10 | 1.67 |
| 2026-04-09 | 1.69 |
| 2026-04-08 | 1.75 |
| 2026-04-07 | 1.64 |
| 2026-04-02 | 1.75 |
| 2026-04-01 | 1.74 |
| 2026-03-31 | 1.69 |
| 2026-03-30 | 1.65 |
| 2026-03-27 | 1.64 |
| 2026-03-26 | 1.63 |
| 2026-03-25 | 1.71 |
| 2026-03-24 | 1.68 |
| 2026-03-23 | 1.82 |
| 2026-03-20 | 1.82 |
| 2026-03-19 | 1.84 |
| 2026-03-18 | 1.85 |
| 2026-03-17 | 1.88 |
| 2026-03-16 | 1.93 |
| 2026-03-13 | 1.93 |
| 2026-03-12 | 1.98 |
| 2026-03-11 | 2.04 |
| 2026-03-10 | 2.10 |
| 2026-03-09 | 2.03 |
| 2026-03-06 | 2.08 |
| 2026-03-05 | 2.10 |
| 2026-03-04 | 2.17 |
| 2026-03-03 | 2.11 |
| 2026-03-02 | 2.18 |
| 2026-02-27 | 2.21 |
| 2026-02-26 | 2.26 |
| 2026-02-25 | 2.25 |
| 2026-02-24 | 2.18 |
| 2026-02-23 | 2.18 |
| 2026-02-20 | 2.20 |
| 2026-02-19 | 2.24 |
| 2026-02-18 | 2.24 |
| 2026-02-17 | 2.23 |
| 2026-02-16 | 2.23 |
| 2026-02-13 | 2.23 |
| 2026-02-12 | 2.24 |
| 2026-02-11 | 2.28 |
| 2026-02-10 | 2.34 |
| 2026-02-09 | 2.27 |
| 2026-02-06 | 2.21 |
| 2026-02-05 | 2.29 |